413 related articles for article (PubMed ID: 9016350)
21. Mu and kappa1 opioid-stimulated [35S]guanylyl-5'-O-(gamma-thio)-triphosphate binding in cynomolgus monkey brain.
Sim-Selley LJ; Daunais JB; Porrino LJ; Childers SR
Neuroscience; 1999; 94(2):651-62. PubMed ID: 10579225
[TBL] [Abstract][Full Text] [Related]
22. Comparison of [Dmt1]DALDA and DAMGO in binding and G protein activation at mu, delta, and kappa opioid receptors.
Zhao GM; Qian X; Schiller PW; Szeto HH
J Pharmacol Exp Ther; 2003 Dec; 307(3):947-54. PubMed ID: 14534366
[TBL] [Abstract][Full Text] [Related]
23. Opioid peptide receptor studies. 17. Attenuation of chronic morphine effects after antisense oligodeoxynucleotide knock-down of RGS9 protein in cells expressing the cloned Mu opioid receptor.
Xu H; Wang X; Wang J; Rothman RB
Synapse; 2004 Jun; 52(3):209-17. PubMed ID: 15065220
[TBL] [Abstract][Full Text] [Related]
24. Anatomical distribution of mu, delta, and kappa opioid- and nociceptin/orphanin FQ-stimulated [35S]guanylyl-5'-O-(gamma-thio)-triphosphate binding in guinea pig brain.
Sim LJ; Childers SR
J Comp Neurol; 1997 Oct; 386(4):562-72. PubMed ID: 9378852
[TBL] [Abstract][Full Text] [Related]
25. Effects of morphine withdrawal on micro-opioid receptor-stimulated guanylyl 5'-[gamma-[35S]thio]-triphosphate autoradiography in rat brain.
Kirschke C; Schadrack J; Zieglgänsberger W; Spanagel R
Eur J Pharmacol; 2002 Jun; 446(1-3):43-51. PubMed ID: 12098584
[TBL] [Abstract][Full Text] [Related]
26. Chronic exposure to mu-opioid agonists produces constitutive activation of mu-opioid receptors in direct proportion to the efficacy of the agonist used for pretreatment.
Liu JG; Prather PL
Mol Pharmacol; 2001 Jul; 60(1):53-62. PubMed ID: 11408600
[TBL] [Abstract][Full Text] [Related]
27. Delta opioid modulation of the binding of guanosine-5'-O-(3-[35S]thio)triphosphate to NG108-15 cell membranes: characterization of agonist and inverse agonist effects.
Szekeres PG; Traynor JR
J Pharmacol Exp Ther; 1997 Dec; 283(3):1276-84. PubMed ID: 9400003
[TBL] [Abstract][Full Text] [Related]
28. Differential involvement of mu(1)-opioid receptors in endomorphin- and beta-endorphin-induced G-protein activation in the mouse pons/medulla.
Mizoguchi H; Narita M; Wu H; Narita M; Suzuki T; Nagase H; Tseng LF
Neuroscience; 2000; 100(4):835-9. PubMed ID: 11036217
[TBL] [Abstract][Full Text] [Related]
29. [(35)S]GTPγS binding and opioid tolerance and efficacy in mouse spinal cord.
Madia PA; Navani DM; Yoburn BC
Pharmacol Biochem Behav; 2012 Mar; 101(1):155-65. PubMed ID: 22108651
[TBL] [Abstract][Full Text] [Related]
30. Involvement of spinal protein kinase Cgamma in the attenuation of opioid mu-receptor-mediated G-protein activation after chronic intrathecal administration of [D-Ala2,N-MePhe4,Gly-Ol(5)]enkephalin.
Narita M; Mizoguchi H; Narita M; Nagase H; Suzuki T; Tseng LF
J Neurosci; 2001 Jun; 21(11):3715-20. PubMed ID: 11356858
[TBL] [Abstract][Full Text] [Related]
31. Effect of strain and sex on mu opioid receptor-mediated G-protein activation in rat brain.
Selley DE; Herbert JT; Morgan D; Cook CD; Picker MJ; Sim-Selley LJ
Brain Res Bull; 2003 May; 60(3):201-8. PubMed ID: 12754081
[TBL] [Abstract][Full Text] [Related]
32. The spinal antinociceptive effects of endomorphins in rats: behavioral and G protein functional studies.
Xie H; Woods JH; Traynor JR; Ko MC
Anesth Analg; 2008 Jun; 106(6):1873-81. PubMed ID: 18499626
[TBL] [Abstract][Full Text] [Related]
33. G protein activation by endomorphins in the mouse periaqueductal gray matter.
Narita M; Mizoguchi H; Narita M; Dun NJ; Hwang BH; Endoh T; Suzuki T; Nagase H; Suzuki T; Tseng LF
J Biomed Sci; 2000; 7(3):221-5. PubMed ID: 10810240
[TBL] [Abstract][Full Text] [Related]
34. Relationship of mu opioid receptor binding to activation of G-proteins in specific rat brain regions.
Maher CE; Selley DE; Childers SR
Biochem Pharmacol; 2000 Jun; 59(11):1395-401. PubMed ID: 10751548
[TBL] [Abstract][Full Text] [Related]
35. Region-dependent G-protein activation by mu-, delta 1- and delta 2-opioid receptor agonists in the brain: comparison between the midbrain and forebrain.
Tsuji M; Narita M; Mizoguchi H; Narita M; Ohsawa M; Kamei J; Nagase H; Takeda H; Matsumiya T; Tseng LF
Life Sci; 1999; 65(16):PL233-9. PubMed ID: 10573190
[TBL] [Abstract][Full Text] [Related]
36. Effects of etonitazene consumption and abstinence on the signal transmission of mu-opioid receptors in brain membranes of rats.
May T; Juilfs F; Wolffgramm J
Neurosci Lett; 1999 Nov; 275(2):109-12. PubMed ID: 10568511
[TBL] [Abstract][Full Text] [Related]
37. Activation of the cloned human kappa opioid receptor by agonists enhances [35S]GTPgammaS binding to membranes: determination of potencies and efficacies of ligands.
Zhu J; Luo LY; Li JG; Chen C; Liu-Chen LY
J Pharmacol Exp Ther; 1997 Aug; 282(2):676-84. PubMed ID: 9262330
[TBL] [Abstract][Full Text] [Related]
38. Relationship between rate and extent of G protein activation: comparison between full and partial opioid agonists.
Traynor JR; Clark MJ; Remmers AE
J Pharmacol Exp Ther; 2002 Jan; 300(1):157-61. PubMed ID: 11752111
[TBL] [Abstract][Full Text] [Related]
39. Lack of evidence of kappa2-selective activation of G-proteins: kappa opioid receptor stimulation of [35S] GTPgammaS binding in guinea pig brain.
Childers SR; Xiao R; Vogt L; Sim LJ
Biochem Pharmacol; 1998 Jul; 56(1):113-20. PubMed ID: 9698095
[TBL] [Abstract][Full Text] [Related]
40. Characterization of the binding of [3H][Dmt1]H-Dmt-D-Arg-Phe-Lys-NH2, a highly potent opioid peptide.
Neilan CL; Janvey AJ; Bolan E; Berezowska I; Nguyen TM; Schiller PW; Pasternak GW
J Pharmacol Exp Ther; 2003 Aug; 306(2):430-6. PubMed ID: 12663687
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
